Carlos Juri

Carlos Juri

Auto-generated profile, based on publicly available information

Carlos Juri

Pontificia Universidad Católica de Chile, Chile

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2012 in Neurobiology of Disease
Verified
Journal Article
Closed access
JBJavier Blesa
Javier Blesa
CPChristian Pifl
Christian Pifl
MSM.A. Sánchez-González
M.A. Sánchez-González
CJC. Juri
C. Juri
MGM.A. García-Cabezas
M.A. García-Cabezas
JOJ.A. Obeso
J.A. Obeso

1 February 2010 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
CJCarlos Juri
Carlos Juri
MRMaría Cruz Rodríguez-Oroz
María Cruz Rodríguez-Oroz
JOJose A. Obeso
Jose A. Obeso

1 June 2010 in Neurobiology of Disease
Verified
Journal Article
Closed access
JBJavier Blesa
Javier Blesa
CJCarlos Juri
Carlos Juri
MCMaría Collantes
María Collantes
IPIvan Penuelas
Ivan Penuelas
EPElena Prieto
Elena Prieto
JOJosé A. Obeso
José A. Obeso

1 January 2011 in Frontiers in Systems Neuroscience
Verified
Journal Article
Open access
JBJavier Blesa
Javier Blesa
CJCarlos Juri
Carlos Juri
MGMiguel Á García-Cabezas
Miguel Á García-Cabezas
RARebeca Adánez
Rebeca Adánez
MSMiguel Á Sánchez-González
Miguel Á Sánchez-González
JOJosé A Obeso
José A Obeso
The onset of Parkinson’s disease (PD) is characterized by focal motor features in one body part, which are usually correlated with greater dopaminergic depletion in the contralateral posterior putamen. The role of dopamine (DA) hemispheric differences in the onset and progression of motor symptoms of PD, however, remains undefined. Previous studies have demonstrated that unilateral manipulations of one nigrostriatal system affect contralateral DA turnover, indicating a functional and compensatory inter-dependence of the two nigrostriatal systems. In preliminary data obtained by our group from asymmetric PD patients, a higher asymmetry index as measured by 6-[18F]fluoro-L-dopa (18 F-DOPA) positron emission tomography (PET) was associated with a higher threshold (i.e., greater dopaminergic loss) for the onset of motor symptoms in the less-affected side. To further elucidate the underlying basis for this, we carried out a complementary study in monkeys using PET to assess and correlate the degree of dopaminergic striatal depletion with motor activity. Control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated monkeys with symmetrical lesions were characterized behaviorally and with 18F-DOPA PET. In parallel, an acute lesion was inflicted in the nigrostriatal projection unilaterally in one monkey, generating a 30% dopaminergic depletion in the ipsilateral striatum, which was not associated with any noticeable parkinsonian feature or deficit. The monkey remained asymptomatic for several months. Subsequently, this monkey received systemic MPTP, following which motor behavior and PET were repeatedly evaluated during progression of parkinsonian signs. The brains of all monkeys were processed using immunohistochemical methods. Our results suggest that the onset of motor signs is related to and influenced by the dopaminergic status of the less-affected, contralateral striatum. Although this work is still preliminary, the study agrees with our general hypothesis of hemispheric inter-dependence in the compensation of striatal DA deficit in PD.

1 November 2010 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
Rodrigo SomozaRodrigo Somoza
Rodrigo Somoza
CJCarlos Juri
Carlos Juri
MBMauricio Baes
Mauricio Baes
UWUrsula Wyneken
Ursula Wyneken
FRFrancisco Javier Rubio
Francisco Javier Rubio
It is thought that the ability of human mesenchymal stem cells (hMSC) to deliver neurotrophic factors might be potentially useful for the treatment of neurodegenerative disorders. The aim of the present study was to characterize signals and/or molecules that regulate brain-derived neurotrophic factor (BDNF) protein expression/delivery in hMSC cultures and evaluate the effect of epigenetically generated BDNF-secreting hMSC on the intact and lesioned substantia nigra (SN). We tested 4 different culture media and found that the presence of fetal bovine serum (FBS) decreased the expression of BDNF, whereas exogenous addition of epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) to serum-free medium was required to induce BDNF release (125 ± 12 pg/day/10⁶ cells). These cells were called hM(N)SC. Although the induction medium inhibited the expression of alpha smooth muscle actin (ASMA), an hMSC marker, and increased the nestin-positive subpopulation of hMSC cultures, the ability to express BDNF was restricted to the nestin-negative subpopulation. One week after transplantation into the SN, the human cells integrated into the surrounding tissue, and some showed a dopaminergic phenotype. We also observed the activation of Trk receptors for neurotrophic factors around the implant site, including the BDNF receptor TrkB. When we transplanted these cells into the unilateral lesioned SN induced by striatal injection of 6-hydroxydopamine (6-OHDA), a significant hypertrophy of nigral tyrosine hydroxylase (TH)(+) cells, an increase of striatal TH-staining and stabilization of amphetamine-induced motor symptoms were observed. Therefore, hMSC cultures exposed to the described induction medium might be highly useful as a vehicle for neurotrophic delivery to the brain and specifically are strong candidates for future therapeutic application in Parkinson's disease.

27 August 2011 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
EPElena Prieto
Elena Prieto
MCMaría Collantes
María Collantes
MDMercedes Delgado
Mercedes Delgado
CJCarlos Juri
Carlos Juri
LGLuis García García
Luis García García
IPIvan Penuelas
Ivan Penuelas